{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:24:34Z","timestamp":1787181874817,"version":"build-2736575974"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119768","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:50:04Z","timestamp":1784238604000},"page":"119768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pleiotropic effects of direct oral anticoagulants on the coagulation\u2013inflammation\u2013endothelium axis: A phenotype-stratified narrative review"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7731-6367","authenticated-orcid":false,"given":"\u0141ukasz","family":"Wo\u0142owiec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Weso\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Skibicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4270-1425","authenticated-orcid":false,"given":"Albert","family":"Ja\u015bniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Osiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wo\u0142owiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Skibicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6669-5931","authenticated-orcid":false,"given":"Grzegorz","family":"Grze\u015bk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biopha.2026.119768_bib1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.biopha.2026.119768_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cvr\/cvt343","article-title":"Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants","volume":"101","author":"Spronk","year":"2014","journal-title":"Cardiovasc. Res."},{"issue":"6801","key":"10.1016\/j.biopha.2026.119768_bib3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signalling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119768_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1244098","article-title":"Distinct pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: a comprehensive review","volume":"14","author":"Atzemian","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119768_bib5","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3390\/antiox12061185","article-title":"Antioxidant properties of oral antithrombotic therapies in atherosclerotic disease and atrial fibrillation","volume":"12","author":"Falco","year":"2023","journal-title":"Antioxid. (Basel)"},{"issue":"8","key":"10.1016\/j.biopha.2026.119768_bib6","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3390\/biomedicines10081890","article-title":"Direct oral anticoagulants (DOACs) for therapeutic targeting of thrombin, a key mediator of cerebrovascular and neuronal dysfunction in Alzheimer's disease","volume":"10","author":"Grossmann","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.biopha.2026.119768_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4081\/btvb.2022.50","article-title":"Pleiotropic effects of anti-thrombotic therapies: have direct oral anticoagulants any anti-inflammatory effect?","volume":"1","author":"Gori","year":"2022","journal-title":"Bleeding Thromb. Vasc. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119768_bib8","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3390\/molecules29112651","article-title":"Pleiotropic effects of direct oral anticoagulants in chronic heart failure and atrial fibrillation: machine learning analysis","volume":"29","author":"Mele","year":"2024","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.biopha.2026.119768_bib9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cvr\/cvag043","article-title":"Anticoagulants beyond coagulation: a narrative review of cardiovascular effects","volume":"122","author":"Aarts","year":"2026","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119768_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad252","article-title":"Oral anticoagulant treatment and risk of kidney disease --- a nationwide, population-based cohort study","volume":"17","author":"Vestergaard","year":"2024","journal-title":"Clin. Kidney J."},{"issue":"15","key":"10.1016\/j.biopha.2026.119768_bib11","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.3390\/jcm12154969","article-title":"Therapeutic drug monitoring of direct oral anticoagulants in patients with extremely low and high body weight --- pilot study","volume":"12","author":"Wo\u0142owiec","year":"2023","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119768_bib12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/jcbfm.2015.9","article-title":"Dabigatran abrogates brain endothelial cell permeability in response to thrombin","volume":"35","author":"Hawkins","year":"2015","journal-title":"J. Cereb. Blood Flow. Metab."},{"issue":"14","key":"10.1016\/j.biopha.2026.119768_bib13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.biopha.2026.119768_bib14","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.biopha.2026.119768_bib15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.biopha.2026.119768_bib16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2510703","article-title":"COBRRA Trial Investigators. Bleeding risk with apixaban vs. rivaroxaban in acute venous thromboembolism","volume":"394","author":"Castellucci","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119768_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/jamacardio.2026.0026","article-title":"APERITIF study investigators. Low-dose rivaroxaban to prevent left ventricular thrombosis after anterior myocardial infarction: the APERITIF randomized clinical trial","volume":"11","author":"Puymirat","year":"2026","journal-title":"JAMA Cardiol."},{"issue":"17","key":"10.1016\/j.biopha.2026.119768_bib18","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.2021.17272","article-title":"Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial","volume":"326","author":"Connors","year":"2021","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.biopha.2026.119768_bib19","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00125-021-05562-9","article-title":"Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers","volume":"64","author":"Pistrosch","year":"2021","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.biopha.2026.119768_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FJC.0000000000001382","article-title":"Dual pathway inhibition with rivaroxaban and aspirin reduces inflammatory biomarkers in atherosclerosis","volume":"81","author":"Russo","year":"2023","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119768_bib21","article-title":"S. Inhibitory effect of rivaroxaban on protease-activated receptor-2 in circulating neutrophils among patients with atrial fibrillation","volume":"52","author":"Nakano","year":"2024","journal-title":"Int. J. Cardiol. Heart Vasc."},{"issue":"12","key":"10.1016\/j.biopha.2026.119768_bib22","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jacbts.2021.09.010","article-title":"Rivaroxaban, a direct oral factor Xa inhibitor, attenuates atherosclerosis by alleviating factor Xa--PAR2-mediated autophagy suppression","volume":"6","author":"Ito","year":"2021","journal-title":"JACC Basic. Transl. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2026.119768_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292628","article-title":"Xa inhibitor edoxaban ameliorates hepatic ischemia-reperfusion injury via PAR-2--ERK 1\/2 pathway","volume":"19","author":"Maeda","year":"2024","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119768_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41419-025-07428-z","article-title":"Non-classical neutrophil extracellular traps induced by PAR2-signaling proteases","volume":"16","author":"Bryzek","year":"2025","journal-title":"Cell. Death Dis."},{"issue":"2","key":"10.1016\/j.biopha.2026.119768_bib25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jtha.2024.10.025","article-title":"Long-term FXa inhibition attenuates thromboinflammation after acute myocardial infarction and stroke by platelet proteome alteration","volume":"23","author":"Polzin","year":"2025","journal-title":"J. Thromb. Haemost."},{"issue":"1-3","key":"10.1016\/j.biopha.2026.119768_bib26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2013.09.006","article-title":"Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue","volume":"718","author":"Bukowska","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119768_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112679","article-title":"Dabigatran: its protective effect against endothelial cell damage by oxysterol","volume":"147","author":"Gorzelak-Pabi\u015b","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.biopha.2026.119768_bib28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/1440-1681.13668","article-title":"Expression of anti- and pro-inflammatory genes in human endothelial cells activated by 25-hydroxycholesterol: a comparison of rivaroxaban and dabigatran","volume":"49","author":"Gorzelak-Pabi\u015b","year":"2022","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.biopha.2026.119768_bib29","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ibneur.2025.11.007","article-title":"Impact of direct oral anticoagulants on blood-brain barrier integrity","volume":"19","author":"Sato","year":"2025","journal-title":"IBRO Neurosci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2026.119768_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.biopha.2026.119768_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"10","key":"10.1016\/j.biopha.2026.119768_bib32","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.biopha.2026.119768_bib33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non--vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.biopha.2026.119768_bib34","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/cvr\/cvaa263","article-title":"Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment","volume":"117","author":"Ten Cate","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"16","key":"10.1016\/j.biopha.2026.119768_bib35","doi-asserted-by":"crossref","first-page":"8727","DOI":"10.3390\/ijms25168727","article-title":"Beyond anticoagulation: a comprehensive review of non-vitamin K oral anticoagulants (NOACs) in inflammation and protease-activated receptor signaling","volume":"25","author":"Jannati","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119768_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00281-011-0289-1","article-title":"Protease-activated receptor 2 signaling in inflammation","volume":"34","author":"Rothmeier","year":"2012","journal-title":"Semin. Immunopathol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119768_bib37","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","article-title":"The mechanism of action of rivaroxaban --- an oral, direct Factor Xa inhibitor --- compared with other anticoagulants","volume":"127","author":"Samama","year":"2011","journal-title":"Thromb. Res."},{"issue":"10264","key":"10.1016\/j.biopha.2026.119768_bib38","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2026.119768_bib39","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5603\/AHP.a2021.0039","article-title":"Therapeutic monitoring of direct oral anticoagulants --- an 8-year observational study","volume":"52","author":"Grze\u015bk","year":"2021","journal-title":"Acta Haematol. Pol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119768_bib40","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0092-8674(91)90261-V","article-title":"Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation","volume":"64","author":"Vu","year":"1991","journal-title":"Cell"},{"issue":"50","key":"10.1016\/j.biopha.2026.119768_bib41","doi-asserted-by":"crossref","first-page":"E1372","DOI":"10.1073\/pnas.1112482108","article-title":"Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through \u03b2-arrestin and dishevelled-2 scaffolds","volume":"108","author":"Soh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119768_bib42","article-title":"Protease-activated receptor 2 at the intersection of thrombo-inflammation and beyond","volume":"52","author":"Fender","year":"2024","journal-title":"Int. J. Cardiol. Heart Vasc."},{"issue":"13","key":"10.1016\/j.biopha.2026.119768_bib43","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1073\/pnas.0700763104","article-title":"Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization","volume":"104","author":"McLaughlin","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2026.119768_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15592-x","article-title":"Effects of intermittent hypoxia with thrombin in an in vitro model of human brain endothelial cells and their impact on PAR-1\/PAR-3 cleavage","volume":"12","author":"Zolotoff","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119768_bib45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrd3615","article-title":"Targeting proteinase-activated receptors: therapeutic potential and challenges","volume":"11","author":"Ramachandran","year":"2012","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"4","key":"10.1016\/j.biopha.2026.119768_bib46","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/jth.15642","article-title":"Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity","volume":"20","author":"D\u00f3lleman","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.biopha.2026.119768_bib47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"36","key":"10.1016\/j.biopha.2026.119768_bib48","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"21","key":"10.1016\/j.biopha.2026.119768_bib49","doi-asserted-by":"crossref","first-page":"8674","DOI":"10.1073\/pnas.1301059110","article-title":"Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice","volume":"110","author":"Martinod","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"18","key":"10.1016\/j.biopha.2026.119768_bib50","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2013-10-463646","article-title":"Thrombosis: tangled up in NETs","volume":"123","author":"Martinod","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2026.119768_bib51","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1538-7836.2008.03204.x","article-title":"Mitochondrial reactive oxygen species: a common pathway for PAR1- and PAR2-mediated tissue factor induction in human endothelial cells","volume":"7","author":"Banfi","year":"2009","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.biopha.2026.119768_bib52","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3390\/ijms21061953","article-title":"The protective effect of dabigatran and rivaroxaban on DNA oxidative changes in a model of vascular endothelial damage with oxidized cholesterol","volume":"21","author":"Wo\u017aniak","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119768_bib53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3892\/etm.2026.13069","article-title":"Effect of rivaroxaban on DNA damage in an ischemia-reperfusion model: evaluation of 8-OHdG levels","volume":"31","author":"Sayarer","year":"2026","journal-title":"Exp. Ther. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119768_bib54","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2021.1956284","article-title":"Rivaroxaban protects from the oxysterol-induced damage and inflammatory activation of the vascular endothelium","volume":"9","author":"Gorzelak-Pabi\u015b","year":"2021","journal-title":"Tissue Barriers"},{"issue":"8","key":"10.1016\/j.biopha.2026.119768_bib55","first-page":"2335","article-title":"Direct factor Xa inhibition attenuates acute lung injury progression via modulation of the PAR-2\/NF-\u03baB signaling pathway","volume":"10","author":"Shi","year":"2018","journal-title":"Am. J. Transl. Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119768_bib56","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10557-020-07010-z","article-title":"Apixaban downregulates endothelial inflammatory and prothrombotic phenotype in an in vitro model of endothelial dysfunction in uremia","volume":"35","author":"Torramade-Moix","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119768_bib57","first-page":"22","article-title":"Rivaroxaban as a protector of oxidative stress-induced vascular endothelial glycocalyx damage via the IQGAP1\/PAR1-2\/PI3K\/Akt pathway","volume":"62","author":"Kitasato","year":"2025","journal-title":"J. Vasc. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119768_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47474-0","article-title":"Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice","volume":"9","author":"Pham","year":"2019","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.biopha.2026.119768_bib59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11883-017-0678-6","article-title":"Oxidative stress in atherosclerosis","volume":"19","author":"Kattoor","year":"2017","journal-title":"Curr. Atheroscler. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2026.119768_bib60","doi-asserted-by":"crossref","first-page":"R1014","DOI":"10.1152\/ajpregu.00124.2004","article-title":"Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology","volume":"287","author":"Li","year":"2004","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119768_bib61","first-page":"392","article-title":"The blood coagulation system as a molecular machine","volume":"82","author":"Spronk","year":"2009","journal-title":"Cardiovasc. Res."},{"issue":"21","key":"10.1016\/j.biopha.2026.119768_bib62","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70927","article-title":"Duration-dependent effects of rivaroxaban on inflammation and valve calcification in aortic stenosis: clinical and in vitro insights","volume":"29","author":"Kopytek","year":"2025","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.biopha.2026.119768_bib63","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s44411-025-00205-6","article-title":"Protective effects of direct oral anticoagulants in an experimental ischemia-reperfusion model","volume":"126","author":"Barbarus","year":"2025","journal-title":"Bratisl. Med. J."},{"issue":"2","key":"10.1016\/j.biopha.2026.119768_bib64","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5606\/tgkdc.dergisi.2022.22831","article-title":"Direct oral anticoagulant agents attenuate temporary aortic occlusion-induced renal oxidative and inflammatory responses in rats","volume":"30","author":"Durmaz","year":"2022","journal-title":"Turk. Gogus Kalp Damar Cerrah-.-. Derg."},{"issue":"17","key":"10.1016\/j.biopha.2026.119768_bib65","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.3390\/ijms20174140","article-title":"Edoxaban exerts antioxidant effects through FXa inhibition and direct radical-scavenging activity","volume":"20","author":"Narita","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119768_bib66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.brainres.2019.05.024","article-title":"Direct oral anticoagulants are associated with limited damage of endothelial cells of the blood-brain barrier mediated by the thrombin\/PAR-1 pathway","volume":"1719","author":"Puech","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2026.119768_bib67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.thromres.2019.02.014","article-title":"Direct oral anticoagulant (DOAC)-mediated vasodilation: role of nitric oxide","volume":"176","author":"Mabley","year":"2019","journal-title":"Thromb. Res."},{"issue":"14","key":"10.1016\/j.biopha.2026.119768_bib68","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","article-title":"Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease","volume":"379","author":"Zannad","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10319","key":"10.1016\/j.biopha.2026.119768_bib69","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE)","volume":"399","author":"Ramacciotti","year":"2022","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.biopha.2026.119768_bib70","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai-VTE Investigators","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119768_bib71","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.thromres.2020.06.046","article-title":"Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation","volume":"195","author":"Correale","year":"2020","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119768_bib72","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/heartjnl-2018-313351","article-title":"Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation","volume":"105","author":"Christersson","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.biopha.2026.119768_bib73","article-title":"Beneficial effect of edoxaban on preventing atrial fibrillation and coagulation by reducing inflammation via HBG1\/HBD biomarkers","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119768_bib74","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40360-024-00785-z","article-title":"A comprehensive insight from molecular docking and dynamics with clinical investigation on the impact of direct oral anticoagulants on atheroprotective protein in atrial fibrillation","volume":"25","author":"Sudhan","year":"2024","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"10291","key":"10.1016\/j.biopha.2026.119768_bib75","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer: the ACTION randomised clinical trial","volume":"397","author":"Lopes","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2026.119768_bib76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119768_bib77","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jcin.2022.01.285","article-title":"Prophylactic rivaroxaban therapy for left ventricular thrombus after anterior ST-segment elevation myocardial infarction","volume":"15","author":"Zhang","year":"2022","journal-title":"JACC Cardiovasc. Interv."},{"issue":"12","key":"10.1016\/j.biopha.2026.119768_bib78","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.biopha.2026.119768_bib79","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.biopha.2026.119768_bib80","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119768_bib81","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119768_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106335","article-title":"Put out the fire: the pleiotropic effect of non-vitamin K oral anticoagulants on the inflammatory pathway","volume":"182","author":"Russo","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119768_bib83","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","article-title":"Growth differentiation factor 15 as a biomarker in cardiovascular disease","volume":"63","author":"Wollert","year":"2017","journal-title":"Clin. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2026.119768_bib84","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1053\/j.ajkd.2009.04.024","article-title":"Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases","volume":"54","author":"Brodsky","year":"2009","journal-title":"Am. J. Kidney Dis."},{"issue":"2","key":"10.1016\/j.biopha.2026.119768_bib85","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ki.2011.44","article-title":"Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate","volume":"80","author":"Brodsky","year":"2011","journal-title":"Kidney Int."},{"issue":"12","key":"10.1016\/j.biopha.2026.119768_bib86","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1681\/ASN.2018070741","article-title":"Anticoagulant-related nephropathy","volume":"29","author":"Brodsky","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119768_bib87","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/ndt\/gft380","article-title":"Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats","volume":"29","author":"Ryan","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"issue":"4","key":"10.1016\/j.biopha.2026.119768_bib88","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11239-013-1019-4","article-title":"Factor-Xa inhibitors protect against systemic oxidant damage induced by peripheral-ischemia reperfusion","volume":"37","author":"Caliskan","year":"2014","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.biopha.2026.119768_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117663","article-title":"Inflammatory protein signatures associated with high rivaroxaban exposure","volume":"245","author":"Feliu","year":"2026","journal-title":"Biochem. Pharmacol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:45:16Z","timestamp":1787179516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":89,"alternative-id":["S0753332226008048"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119768","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pleiotropic effects of direct oral anticoagulants on the coagulation\u2013inflammation\u2013endothelium axis: A phenotype-stratified narrative review","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119768"}}